Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Determinants and associations of health-related quality of life with mortality in acute and chronic heart failure: findings from the ESC HF III Registry

Walli-Attaei M., Lund LH., Luengo-Fernandez R., Gray A., Torbica A., Huculeci R., Aboyans V., Timmis AD., Vardas P., Maggioni AP., Leal J.

Aims: To assess the demographic, clinical, behavioural, and treatment factors associated with health-related quality of life (HRQoL) in heart failure (HF), examine the association between HRQoL and mortality, and evaluate changes in HRQoL over 1-year. Methods: We analysed the ESC EORP Heart Failure III Registry, including patients hospitalised with acute HF or outpatient HF visits. HRQoL was assessed using the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Generalised linear models examined associations between demographic, clinical, behavioural, and treatment characteristics with baseline HRQoL. Cox proportional hazards models assessed the relationship between baseline HRQoL and 1-year mortality. Changes in HRQoL were classified as improvement, deterioration, or mixed change across EQ-5D dimensions, and determinants of change were assessed using fixed-effects models. Results: Among 10,130 patients (acute HF: 38.6%; outpatient HF: 61.4%), those with acute HF had worse baseline HRQoL than outpatients. Older age, female sex, eGFR≤29, NYHA class III/IV, and dyspnoea at rest were strongly associated with lower HRQoL in both acute and outpatient HF. Lower baseline HRQoL was associated with a higher risk of death at one year, with a 0.1-unit decrease in HRQoL on a scale of -0.59 to 1.00 (equivalent to 37 days of full health lost annually) associated with a 9% higher risk of death; a finding consistent across ejection fraction categories and sex. At 1-year, 45% of patients reported improved HRQoL, and improvements were more common in those with acute HF, mildly reduced ejection fraction, and women. Use of ACEi/ARBs/ARNIs was associated with a modest improvement in HRQoL at 1 year. Conclusions: HRQoL provides important clinical information and may provide additional insight into patients’ health status and disease progression beyond conventional clinical measures.